Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 3;5(Suppl 1):i5-i12.
doi: 10.1093/noajnl/vdad020. eCollection 2023 May.

The joint impacts of sex and race/ethnicity on incidence of grade 1 versus grades 2-3 meningioma across the lifespan

Kyle M Walsh  1   2   3 , Mackenzie Price  1   4 , Corey Neff  1   4 , Jordan M Komisarow  1 , Courtney E Wimberly  1 , Carol Kruchko  4 , Jill S Barnholtz-Sloan  5   4 , Quinn T Ostrom  1   2   3   4
Affiliations

The joint impacts of sex and race/ethnicity on incidence of grade 1 versus grades 2-3 meningioma across the lifespan

Kyle M Walsh et al. Neurooncol Adv. .

Abstract

Background: Previous research has identified older age, African-American race, and female sex as meningioma risk factors, but there is limited information on their joint effects, or on how these demographic factors vary across strata of tumor grade.

Methods: The Central Brain Tumor Registry of the United States (CBTRUS) is a population-based registry combining data from the CDC's National Program of Cancer Registries and NCI's Surveillance, Epidemiology and End Results Program which covers ~100% of the U.S. population and aggregates incidence data on all primary malignant and nonmalignant brain tumors. These data were used to explore the joint impacts of sex and race/ethnicity on average annual age-adjusted incidence rates of meningioma. We calculated meningioma incidence rate ratios (IRRs) by sex and race/ethnicity, across strata of age and tumor grade.

Results: Compared to individuals who are non-Hispanic White, individuals who are non-Hispanic Black had significantly higher risk of grade 1 (IRR = 1.23; 95% CI: 1.21-1.24) and grade 2-3 meningioma (IRR = 1.42; 95% CI: 1.37-1.47). The female-to-male IRR peaked in the fifth decade of life across all racial/ethnic groups and tumor grades, but was 3.59 (95% CI: 3.51-3.67) for WHO grade 1 meningioma and 1.74 (95% CI: 1.63-1.87) for WHO grade 2-3 meningioma.

Conclusions: This study reveals the joint effects of sex and race/ethnicity on meningioma incidence throughout the lifespan and across strata of tumor grade, highlighting incidence disparities among females and African-Americans that may inform future strategies for tumor interception.

Keywords: African Americans; epidemiology; incidence; meningioma; racial disparities.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Average annual age-adjusted incidence rate and 95% confidence interval (CI) for meningioma by race/ethnicity and stratified by grade. Incidence rate ratios (IRR) and their 95% CI appear above bars and are calculated relative to non-Hispanic White individuals as the reference. Rates are age-adjusted to the 2000 US standard population (CBTRUS: Data provided by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2004-2019).
Figure 2.
Figure 2.
Female-to-male incidence rate ratios and 95% confidence intervals (CI) for meningioma, stratified by age group at diagnosis (CBTRUS: Data provided by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2004-2019).
Figure 3.
Figure 3.
Female-to-male incidence rate ratios for meningioma, by age group at diagnosis, and stratified by race/ethnicity (CBTRUS: Data provided by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2004-2019).
Figure 4.
Figure 4.
Female-to-male incidence rate ratios and 95% confidence intervals (CI) for meningioma, by age group at diagnosis and stratified by WHO tumor grade (CBTRUS: Data provided by CDC’s National Program of Cancer Registries and NCI’s Surveillance, Epidemiology and End Results Program, 2004-2019).
See this image and copyright information in PMC

References

    1. Ostrom QT, Price M, Neff C, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro Oncol. 2022; 24(Supplement_5):v1–v95. - PMC - PubMed
    1. Lin DD, Lin JL, Deng XY, et al. . Trends in intracranial meningioma incidence in the United States, 2004-2015. Cancer Med. 2019; 8(14):6458–6467. - PMC - PubMed
    1. Huntoon K, Toland AMS, Dahiya SM.. A review of clinicopathological and molecular aspects. Front Oncol. 2020; 10:579599. - PMC - PubMed
    1. Kshettry VR, Ostrom QT, Kruchko C, et al. . Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015; 17(8):1166–1173. - PMC - PubMed
    1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23(8):1231–1251. - PMC - PubMed

LinkOut - more resources